nach oben

Drugs & Aging

Erschienen in:

01.07.2007 | Therapy In Practice

Epidemiology and Management of Apathy in Patients with Alzheimer’s Disease

verfasst von: Romina Mizrahi, Prof. Sergio E. Starkstein

Erschienen in: Drugs & Aging | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Although apathy is a diagnostic term used with increasing frequency in both neurology and psychiatry, confusion still exists as to its proper definition and assessment, and whether apathy should be considered a symptom of major psychiatric diseases or an independent syndrome in its own right. Moreover, critical questions regarding the phenomenology and clinical correlates of apathy and the syndromic validity of this construct still exist. Despite these nosological concerns, there is strong evidence that apathy is a common finding in Alzheimer’s disease (AD). However, the treatment of apathy is still elusive. Current data are obtained from randomised controlled trials that did not investigate apathy per se, but rather a number of other behavioural and psychological variables. In this context, acetylcholinesterase inhibitors and psychosocial interventions are the only available modalities for treating apathy in AD with some efficacy.

Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3(3): 243–54PubMed

Starkstein SE. Apathy and withdrawal. Int Psychogeriatr 2000; 12Suppl. 1: 135–8CrossRef

van Reekum R, Stuss DT, Ostrander L. Apathy: why care? J Neuropsychiatry Clin Neurosci 2005; 17(1): 7–19PubMedCrossRef

Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil 2005; 20(4): 377–88PubMedCrossRef

Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cerebral Cortex 2006; 16(7): 916–28PubMedCrossRef

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association, 1994

World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders. Geneva: WHO, 1993

Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry 1990; 147(1): 22–30PubMed

Starkstein SE, Fedoroff JP, Price TR, et al. Apathy following cerebrovascular lesions. Stroke 1993; 24(11): 1625–30PubMedCrossRef

10.

Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4(2): 134–9PubMed

11.

Starkstein SE, Migliorelli R, Manes F, et al. The prevalence and clinical correlates of apathy and irritability in Alzheimer’s disease. Eur J Neurol 1995; 2: 540–6CrossRef

12.

Starkstein SE, Merello M. Psychiatric and cognitive disorders in Parkinson’s disease. Cambridge: Cambridge University Press, 2002CrossRef

13.

Starkstein SE, Petracca G, Chemerinski E, et al. Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry 2001; 158(6): 872–7PubMedCrossRef

14.

Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998; 10(3): 314–9PubMed

15.

Starkstein SE, Garau ML, Cao A. Prevalence and clinical correlates of disinhibition in dementia. Cogn Behav Neurol 2004; 17: 139–47PubMedCrossRef

16.

Buettner L, Fitzsimmons S. Mixed behaviors in dementia: the need for a paradigm shift. J Gerontol Nurs 2006; 32(7): 15–22PubMed

17.

Marin RS, Butters MA, Mulsant BH, et al. Apathy and executive function in depressed elderly. J Geriatr Psychiatry Neurol 2003; 16(2): 112–6PubMedCrossRef

18.

Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis 1994; 182(4): 235–9PubMedCrossRef

19.

Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48Suppl. 6: S10–6PubMedCrossRef

20.

Strauss ME, Sperry SD. An informant-based assessment of apathy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15(3): 176–83PubMed

21.

Robert PH, Clairet S, Benoit M, et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002; 17(12): 1099–105PubMedCrossRef

22.

Starkstein SE, Ingram L, Garau LM, et al. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry 2005; 76: 1070–4PubMedCrossRef

23.

Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale, and description. Arch Gen Psychiatry 1992; 49(8): 624–9PubMedCrossRef

24.

Tatsch MF, Bottino CM, Azevedo D, et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. Am J Geriatr Psychiatry 2006; 14(5): 438–45PubMedCrossRef

25.

Landes AM, Sperry SD, Strauss ME. Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2005; 17(3): 342–9PubMedCrossRef

26.

Craig D, Mirakhur A, Hart DJ, et al. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2005; 13(6): 460–8PubMed

27.

Thomas P, Clement JP, Hazif-Thomas C, et al. Family, Alzheimer’s disease and negative symptoms. Int J Geriatr Psychiatry 2001; 16(2): 192–202PubMedCrossRef

28.

Starkstein SE, Jorge R, Mizrahi R, et al. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006 Jan; 77(1): 8–11PubMedCrossRef

29.

Boyle PA, Malloy PF, Salloway S, et al. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 214–21PubMed

30.

Robert PH, Berr C, Volteau M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. Clin Neurol Neurosurg 2006; 108(8): 733–6PubMedCrossRef

31.

Ready RE, Ott BR, Grace J, et al. Apathy and executive dysfunction in mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 222–8PubMed

32.

Robert PH, Berr C, Volteau M, et al. Neuropsychological performance in mild cognitive impairment with and without apathy. Dement Geriatr Cogn Disord 2006; 21(3): 192–7PubMedCrossRef

33.

Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157(1): 4–15PubMed

34.

Cummings JL, Nadel A, Masterman D, et al. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 2001; 14(2): 101–8PubMedCrossRef

35.

Cummings JL, Koumaras B, Chen M, et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3(3): 137–48PubMedCrossRef

36.

Herrmann N, Rabheru K, Wang J, et al. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005; 13(6): 527–34PubMed

37.

Mega MS, Dinov ID, Porter V, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005; 62(5): 721–8PubMedCrossRef

38.

Kaufer D, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer’s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998; 10(1): 55–63PubMed

39.

Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997; 9(2): 231–9PubMed

40.

Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990; 24: 73–88PubMed

41.

Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj 2004; 18(1): 1–31PubMedCrossRef

42.

Watanabe MD, Martin EM, DeLeon OA, et al. Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci 1995; 7(4): 502–4PubMed

43.

McAllister TW. Apathy. Semin Clin Neuropsychiatry 2000; 5(4): 275–82PubMedCrossRef

44.

Erkulwater S, Pillai R. Amantadine and the end-stage dementia of Alzheimer’s type. South Med J 1989; 82(5): 550–4PubMedCrossRef

45.

Chapman SB, Weiner MF, Rackley A, et al. Effects of cognitive-communication stimulation for Alzheimer’s disease patients treated with donepezil. J Speech Lang Hear Res 2004; 47(5): 1149–63PubMedCrossRef

46.

Holmes C, Knights A, Dean C, et al. Keep music live: music and the alleviation of apathy in dementia subjects. Int Psychogeriatr 2006; 18(4): 623–30PubMedCrossRef

47.

Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005; 20(4): 301–14PubMedCrossRef

48.

Politis AM, Vozzella S, Mayer LS, et al. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry 2004; 19(11): 1087–94PubMedCrossRef

49.

Overshott R, Byrne J, Burns A. Nonpharmacological and pharmacological interventions for symptoms in Alzheimer’s disease. Expert Rev Neurother 2004; 4(5): 809–21PubMedCrossRef

50.

Boyle PA, Malloy PF. Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 17(1–2): 91–9PubMedCrossRef

Titel: Epidemiology and Management of Apathy in Patients with Alzheimer’s Disease
verfasst von: Romina Mizrahi
Prof. Sergio E. Starkstein
Publikationsdatum: 01.07.2007
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 7/2007
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200724070-00003

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Acute Exacerbations of Chronic Bronchitis in Elderly Patients

Neuroprotective Effects of Free Radical Scavengers in Stroke

Characterisation of Patients with Postmenopausal Osteoporosis in French Primary Healthcare

Sustained-Release Ophthalmic Drug Delivery Systems for Treatment of Macular Disorders

Clinical Perspectives on Bone Quality in Osteoporosis